| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 4, Issue 9 769-776, Copyright © 1993 by American Association of Cancer Research
ARTICLES |
LL Chen, B Gansbacher, E Gilboa, R Taetle, J Oval, MS Hibbs, CK Huang, ML Clawson, S Bilgrami and J Schlessinger
Division of Hematology and Oncology, University of Connecticut Health Center, Farmington 06030.
HL60 cells are devoid of endogenous epidermal growth factor receptor (EGFR). They respond to retinoic acid and undergo terminal granulocytic differentiation. EGFR complementary DNA was introduced into HL60 cells by retroviral gene transfer. Scatchard plot showed that the binding characteristics are identical to those of A431 cells. HL60-EGFR cells were estimated to express 34,000 EGFR/cell (Kd = 5 nM). The tyrosine phosphorylation upon ligand binding is the first step of signal transduction. The dominant phosphotyrosyl proteins in epidermal growth factor-stimulated HL60-EGFR cells include a 170 kDa protein (EGFR itself), and 125 and 53 kDa proteins. The EGFR signal results in the induction of 92 kDa gelatinase/matrix metalloproteinase in HL60-EGFR cells, thereby providing evidence of the function of the exogenous EGFR and a semiquantitative measure of the EGFR signal. These HL60-EGFR cells offer a unique opportunity to examine the potentially important role of EGFR (c-erbB) in maintaining homeostasis between self-renewal and differentiation. c-erbB has been shown to play a physiological role in the self-renewal of the very early avian stem cells which do express EGFR. The v-erbB (double truncated EGFR) has been shown to cause avian erythroblastosis. We found that these HL60-EGFR cells responded to retinoic acid differently from the HL60-control cells. A partial block of only 45% granulocytic differentiation and concomitant proliferation was noted, consistent with a shift of balance between self-renewal and differentiation toward the former.
This article has been cited by other articles:
![]() |
K. Stegmaier, S. M. Corsello, K. N. Ross, J. S. Wong, D. J. DeAngelo, and T. R. Golub Gefitinib induces myeloid differentiation of acute myeloid leukemia Blood, October 15, 2005; 106(8): 2841 - 2848. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takahashi, K. Yamada, T. Tanaka, K. Kumano, M. Kurokawa, T. Takahashi, N. Hirano, H. Honda, S. Chiba, K. Tsuji, et al. A Potential Molecular Approach to Ex Vivo Hematopoietic Expansion With Recombinant Epidermal Growth Factor Receptor-Expressing Adenovirus Vector Blood, June 15, 1998; 91(12): 4509 - 4515. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Lee, G. L. Walsh, M. I. Dawson, W. K. Hong, and J. M. Kurie All-trans-Retinoic Acid Inhibits Jun N-terminal Kinase-dependent Signaling Pathways J. Biol. Chem., March 20, 1998; 273(12): 7066 - 7071. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |